Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Venous Sinus Stenting Outcomes in Patients with Papilledema from Secondary Causes of Elevated Intracranial Pressure.

Neuro-ophthalmology (Aeolus Press)·2026
Same author

Teaching NeuroImages: Topless Optic Disc or Superior Segmental Optic Nerve Hypoplasia.

Neurology·2026
Same author

Jugular Bulb Arteriovenous Fistula Induced Papilledema.

Ophthalmology·2026
Same author

Too much of a good thing.

Survey of ophthalmology·2026
Same author

Epidemiology of Adult-Onset Nystagmus and Saccadic Intrusions of Central Etiologies: A Population-Based Study in Olmsted County.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025
Same author

Neurofilament light chain levels differentiate ischemic from inflammatory optic neuropathies.

Multiple sclerosis and related disorders·2025

Related Experiment Videos

Ocular myasthenia gravis.

Michael S Vaphiades1, M Tariq Bhatti, Robert L Lesser

  • 1Department of Ophthalmology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Current Opinion in Ophthalmology
|October 11, 2012
PubMed
Summary

Ocular myasthenia gravis (OMG) presents unique diagnostic challenges, mimicking other neurological disorders. Effective management requires tailored treatment strategies based on disease severity and patient impact.

Area of Science:

  • Neurology
  • Ophthalmology

Background:

  • Ocular myasthenia gravis (OMG) is a localized form of myasthenia gravis.
  • It specifically affects extraocular muscles, levator palpebrae superioris, and orbicularis oculi muscles.

Purpose of the Study:

  • To review ocular myasthenia gravis (OMG).
  • To highlight its clinical presentation and diagnostic considerations.

Main Methods:

  • Literature review of ocular myasthenia gravis.
  • Analysis of diagnostic challenges and management strategies.

Main Results:

  • Ocular manifestations of OMG can mimic various ocular motility disorders.
  • These include central nervous system disorders and peripheral cranial nerve palsies.

Related Experiment Videos

  • Diagnosis and management are often challenging, despite pupil sparing.

    • Conclusions:

    • Clinicians face challenges in diagnosing and managing OMG.
    • Multiple diagnostic and treatment options exist.
    • Treatment sequencing and combination should be individualized based on disease activity and patient disability.